Neurocrine Bioscience buy The Goldman Sachs Group, Inc.
Start price
25.01.24
/
50%
€128.55
Target price
25.01.25
€140.87
Performance (%)
9.80%
End price
26.01.25
€141.15
Summary
This prediction ended on 26.01.25 with a price of €141.15. With a performance of 9.80%, the BUY prediction by The_Goldman_Sachs_Gr for Neurocrine Bioscience closed with a slight gain. The_Goldman_Sachs_Gr has a follow-up prediction for Neurocrine Bioscience where he still thinks Neurocrine Bioscience is a Buy. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Neurocrine Bioscience | -1.577% | -1.577% | 8.571% |
| iShares Core DAX® | 0.795% | 1.458% | 17.980% |
| iShares Nasdaq 100 | -3.088% | -0.762% | 3.169% |
| iShares Nikkei 225® | -0.952% | -2.268% | 12.208% |
| iShares S&P 500 | -1.393% | 0.199% | 1.698% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Neurocrine Bioscience diskutieren
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $134.00 to $153.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
In the thread Trading Neurocrine Bioscience
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten
Current prediction by The_Goldman_Sachs_Gr for Neurocrine Bioscience
Neurocrine Bioscience
Start price
Target price
Perf. (%)
€114.40
10.07.25
10.07.25
€154.99
10.07.26
10.07.26
14.60%
15.12.25
15.12.25
